Navigation Links
Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Date:10/13/2011

NEW YORK, Oct. 13, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology (JCO).  Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer drug candidate that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway is currently being investigated in a Phase 3 trial comparing perifosine + bortezomib + dexamethasone versus placebo + bortezomib + dexamethasone in relapsed/refractory MM patients previously treated with bortezomib.  The ongoing Phase 3 study is being conducted under a Special Protocol Assessment (SPA), and with Orphan Drug Status and Fast Track designation in MM.  Perifosine is also currently in Phase 3 clinical development for refractory advanced colorectal cancer, also under an SPA and Fast Track designation.

In this Phase 1 / 2 study, perifosine in combination with bortezomib +/- dexamethasone was evaluated in 84 heavily pre-treated patients with relapsed or relapsed/refractory MM.  All patients were required to receive prior bortezomib and most were bortezomib refractory (73%).  The combination demonstrated an overall response rate (ORR) including MR or > of 41% in all evaluable patients, with stable disease observed in an additional 41% of evaluable patients. The ORR was 65% for bortezomib-relapsed patients and 32% for patients with bortezomib-refractory disease. Median progression-free survival (PFS) was 6.4 months, wit
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
4. Hepatitis C Phase 2A Trial Positive Results
5. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
6. Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
7. GeoVax Phase 2a Clinical Trial Completes Enrollment
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
10. Visual Healthcare to Supply Enabling Technology for Home Care Consortium Software and Support Revenues to Reach $17 M in Phase One
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Timothy E. Morris , chief financial officer  will ... the events are as follows: Mizuho Third ... Location:  The Omni Berkshire Place, New York ...
(Date:4/30/2015)... 2015 Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its first quarter ... for the first quarter of 2015 was $116.2 million, ... of 2014, and down $5.3 million or 4.4% from ... 2015 net income as reported in accordance with U.S. ...
(Date:4/30/2015)... JOLLA, Calif. , April 30, 2015   ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended March ... U.S. financial markets close. Regulus will ... 7, 2015, at 5:00 pm Eastern Daylight Time to ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... 27, 2011 Bend Research Inc. ( www.bendresearch.com ), a ... new president. Jim Nightingale, who has worked ... in the firm,s 36-year history. Nightingale will ... Bend Research Chief Executive Officer (CEO) and chairman of the ...
... July 27, 2011 Assured Pharmacy, Inc. (Other OTC: ... to more than 3,000 sufferers of chronic pain, announced ... Kansas for its fifth pharmacy location.  Subject to regulatory ... during the Fourth Quarter of 2011.  It will join ...
Cached Medicine Technology:Bend Research Inc. Names New President 2Assured Pharmacy Signs Lease in Kansas City, Kansas for its Fifth Pharmacy Location 2Assured Pharmacy Signs Lease in Kansas City, Kansas for its Fifth Pharmacy Location 3
(Date:5/2/2015)... “ ActOn ” was featured on NewsWatch as ... the latest and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... to make a difference. , In this material world, almost ... aren’t about money, which is why those things should be ...
(Date:5/2/2015)... 2015 It’s a pattern that won’t ... strikes anywhere on this planet, cyber scammers will immediately ... compassion for their own personal gain. And on ... Team) issued an alert titled “Nepal Earthquake Disaster ... citing the earthquake in Nepal. The scam emails may ...
(Date:5/2/2015)... 02, 2015 “ Peachtree Audio ” ... Tech Report, which features the latest and coolest technology ... and special reporter for NewsWatch, conducted the review and ... equipment. , Music is an important part of ... pampered and given the royal treatment. Peachtree Audio does ...
(Date:5/2/2015)... Chicago, IL (PRWEB) May 02, 2015 Kare ... to provide support for busy caregivers. Kare Visits offers ... hospitals, and assisted living facilities. According to the ... caregivers spend an average of 20 hours a week caring ... fraction of the cost to hire a nurse, a caregiver ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
Breaking Medicine News(10 mins):Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... ... to distributors, re-sellers, and customers. It was ultimately a lavish gift for an industry that ... ... a custom made bottle of a well known whiskey, designed especially for their company. The ...
... Spanish . , Higher rates of colorectal cancer ... by differences in health care utilization, and less by biology, ... National Cancer Institute (NCI), part of the National Institutes of ... people who were screened for colorectal cancer, researchers found that ...
... at initial screening often didn,t have recommended colonoscopy, study ... Americans are less likely than whites to have a ... sigmoidoscopy screening test, says a new study. , ... risk for colorectal cancer and more likely to die ...
... patients often receive better care than normal-weight peers, study ... concerns that obese Americans get second-rate health care, a ... of medical attention they receive versus that of normal-weight ... the obese may actually be higher and more aggressive ...
... support care between office visits, boost efficiency and convenience, ... the April Health Affairs suggests how to ... patients how they like it and what they want. ... health information technology they use is meeting their needs ...
... ... affording it an end to end marketing platform in China. , ... Oakland, CA (PRWEB) April 2, 2010 ... business process outsourcing company, Mag2U, to enhance DDKU’s growing internet presence as well as ...
Cached Medicine News:Health News:Sinrex Male Enhancement Manufacturer Gifts Custom Bottle of Whiskey to Customers 2Health News:New study implicates health care utilization, over biology, in colorectal cancer disparities 2Health News:New study implicates health care utilization, over biology, in colorectal cancer disparities 3Health News:New study implicates health care utilization, over biology, in colorectal cancer disparities 4Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Obese Americans Get High Quality Medical Care 2Health News:Obese Americans Get High Quality Medical Care 3Health News:Want better health information technology? Ask patients how they want it 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 3
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... The INFINITI 4F, 5F, ... diagnostic catheters is ideal ... products incorporate state-of-the-art technology ... to deliver better responsiveness, ...
Medicine Products: